{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:57:37Z","timestamp":1780088257762,"version":"3.54.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.kint.2023.06.029","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T20:57:34Z","timestamp":1688590654000},"page":"803-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing"],"prefix":"10.1016","volume":"104","author":[{"given":"Nicolas","family":"Delaleu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Sekulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarig","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannveig","family":"Skrunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Leh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Gaspert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnar","family":"Flatberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oystein","family":"Eikrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.06.029_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00441-017-2609-9","article-title":"Pathomechanisms of renal Fabry disease","volume":"369","author":"Eikrem","year":"2017","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.kint.2023.06.029_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr Res"},{"key":"10.1016\/j.kint.2023.06.029_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2023.06.029_bib4","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 2","key":"10.1016\/j.kint.2023.06.029_bib5","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.06.029_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.06.029_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2023.06.029_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2023.06.029_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2023.06.029_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.06.029_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13073-016-0388-7","article-title":"Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities","volume":"8","author":"Beckmann","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.kint.2023.06.029_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2023.06.029_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/978-3-319-67144-4_22","article-title":"Personalized medicine: what's in it for rare diseases?","volume":"1031","author":"Schee Genannt Halfmann","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.kint.2023.06.029_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI124611","article-title":"Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases","volume":"130","author":"Agache","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.06.029_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.drudis.2017.10.009","article-title":"Computational drug repositioning for rare diseases in the era of precision medicine","volume":"23","author":"Delavan","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.kint.2023.06.029_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.06.029_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2023.06.029_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149743","article-title":"Transcriptome sequencing (RNAseq) enables utilization of formalin-fixed, paraffin-embedded biopsies with clear cell renal cell carcinoma for exploration of disease biology and biomarker development","volume":"11","author":"Eikrem","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.06.029_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"10.1016\/j.kint.2023.06.029_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.kint.2023.06.029_bib21","doi-asserted-by":"crossref","unstructured":"Sergushichev AA. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. Preprint. bioRxiv. 060012. Posted online June 20, 2016. https:\/\/doi.org\/10.1101\/060012","DOI":"10.1101\/060012"},{"key":"10.1016\/j.kint.2023.06.029_bib22","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.06.029_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013984","article-title":"Enrichment map: a network-based method for gene-set enrichment visualization and interpretation","volume":"5","author":"Merico","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.06.029_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/biomedicines11010226","article-title":"Network-based assessment of minimal change disease identifies glomerular response to IL-7 and IL-12 pathways activation as innovative treatment target","volume":"11","author":"Eikrem","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.kint.2023.06.029_bib25","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar4362","article-title":"Transcriptional landscapes of emerging autoimmunity: transient aberrations in the targeted tissue's extracellular milieu precede immune responses in Sjogren's syndrome","volume":"15","author":"Delaleu","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2023.06.029_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41588-017-0026-3","article-title":"Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2023.06.029_bib27","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","article-title":"Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer","volume":"28","author":"Di Mitri","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.kint.2023.06.029_bib28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41590-020-0622-8","article-title":"A\u00a0molecular network regulating the proinflammatory phenotype of human memory T lymphocytes","volume":"21","author":"Emming","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.kint.2023.06.029_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/0471250953.bi0813s47","article-title":"Biological network exploration with Cytoscape 3","volume":"47","author":"Su","year":"2014","journal-title":"Curr Protoc Bioinformatics"},{"key":"10.1016\/j.kint.2023.06.029_bib30","doi-asserted-by":"crossref","first-page":"bau012","DOI":"10.1093\/database\/bau012","article-title":"COMPARTMENTS: unification and visualization of protein subcellular localization evidence","volume":"2014","author":"Binder","year":"2014","journal-title":"Database (Oxford)"},{"key":"10.1016\/j.kint.2023.06.029_bib31","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.kint.2023.06.029_bib32","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.kint.2023.06.029_bib33","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1681\/ASN.2017020143","article-title":"The evolving complexity of the podocyte cytoskeleton","volume":"28","author":"Schell","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.06.029_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41581-019-0197-5","article-title":"The multifaceted role of iron in renal health and disease","volume":"16","author":"van Swelm","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2023.06.029_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29240-w","article-title":"Urine-derived cells: a promising diagnostic tool in Fabry disease patients","volume":"8","author":"Slaats","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2023.06.029_bib36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1186\/s12885-019-6363-0","article-title":"The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues","volume":"19","author":"Marczyk","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.kint.2023.06.029_bib37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12967-019-1976-2","article-title":"Animal to human translation: a systematic scoping review of reported concordance rates","volume":"17","author":"Leenaars","year":"2019","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.kint.2023.06.029_bib38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/bioinformatics\/btu611","article-title":"Understanding the limits of animal models as predictors of human biology: lessons learned from the sbv IMPROVER Species Translation Challenge","volume":"31","author":"Rhrissorrakrai","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.kint.2023.06.029_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3313","article-title":"Sjogren's syndrome: studying the disease in mice","volume":"13","author":"Delaleu","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2023.06.029_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41436-019-0616-9","article-title":"Developing interactions with industry in rare diseases: lessons learned and continuing challenges","volume":"22","author":"Berry","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2023.06.029_bib41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Guerard","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.kint.2023.06.029_bib42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.06.029_bib43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2023.06.029_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human \u03b1-galactosidase-A enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2023.06.029_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2023.06.029_bib46","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.kint.2023.06.029_bib47","first-page":"221","article-title":"New drugs for the treatment of Anderson-Fabry disease","volume":"34","author":"Feriozzi","year":"2021","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2023.06.029_bib48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and investigational therapeutics for Fabry disease","volume":"5","author":"Felis","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.06.029_bib49","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A\u00a0pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.kint.2023.06.029_bib50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2023.06.029_bib51","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"Muntze","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.kint.2023.06.029_bib52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/postgradmedj-2018-136056","article-title":"Hot topics in Fabry disease","volume":"94","author":"Cairns","year":"2018","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.kint.2023.06.029_bib53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.029_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2023.06.029_bib55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry","volume":"30","author":"Eng","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2023.06.029_bib56","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/rheumatology\/kew013","article-title":"Sjogren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome","volume":"55","author":"Delaleu","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2023.06.029_bib57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/art.39015","article-title":"High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjogren's syndrome","volume":"67","author":"Delaleu","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2023.06.029_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/bs.acc.2016.07.003","article-title":"Urine exosomes: an emerging trove of biomarkers","volume":"78","author":"Street","year":"2017","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.kint.2023.06.029_bib59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2023.06.029_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41592-020-01033-y","article-title":"Method of the year: spatially resolved transcriptomics","volume":"18","author":"Marx","year":"2021","journal-title":"Nat Methods"},{"key":"10.1016\/j.kint.2023.06.029_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol Genet Metab"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823004878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823004878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:05:41Z","timestamp":1758762341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823004878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0085253823004878"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.06.029","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}